Stimrelieve LLC (Fort Lauderdale, Fla.) reported it received an IDE from the FDA to launch a clinical trial of its percutaneously implantable device for the treatment of chronic migraines when compared to more conservative therapies such as NSAIDs, migraine-specific drugs, or combination drug therapy.